Buy Rating Affirmed for Century Therapeutics on Promising CNTY-101 Prospects and Strong Financial Footing

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on IPSC stock, giving a Buy rating on May 10.

Daina Graybosch has given his Buy rating due to a combination of factors including the promising prospects of Century Therapeutics’ leading candidate, CNTY-101, and its potential for clinical differentiation in autoimmune disease (AID) settings. Graybosch sees significant upside in the company’s stock ahead of the updated Phase 1 dose escalation data presentation for CNTY-101 at the American Society of Clinical Oncology (ASCO) meeting. The positive view is also based on the strength of Century’s Allo-Evasion and induced pluripotent stem cell (iPSC) platforms, which are perceived to have an unjustified valuation gap when compared to peers in the allogeneic cell therapy and AID-focused markets.
Furthermore, Graybosch anticipates that a favorable update at ASCO could lessen the perceived risks associated with CNTY-101’s clinical progress, particularly in treating moderate-to-severe systemic lupus erythematosus (SLE). The report also highlights Century’s solid financial position, bolstered by recent funding, which is expected to support their operations and research development well into 2026. Overall, the combination of strong platform technologies, upcoming clinical data readouts, and a robust financial runway have contributed to the Buy rating for Century Therapeutics’ stock.

In another report released on May 10, H.C. Wainwright also maintained a Buy rating on the stock with a $11.00 price target.

IPSC’s price has also changed dramatically for the past six months – from $1.310 to $3.150, which is a 140.46% increase.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Century Therapeutics (IPSC) Company Description:

Century Therapeutics Inc is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with a significant unmet medical need. It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematological malignancies.